Business Context and Reporting Period
The supplied filing is Renovaro Inc.’s unaudited Form 10-Q for the quarter and nine months ended March 31, 2024, filed May 15, 2024. It does not appear to be a filing for Lunai Bioworks Inc. or for 2023 Q3. Renovaro is a pre-revenue biotechnology and artificial-intelligence healthcare company developing cancer, HIV and HBV therapies and, following its February 13, 2024 acquisition of GEDi Cube, AI-driven cancer diagnostics.
The acquisition added Renovaro Cube as a wholly owned subsidiary and expanded the company’s activities into liquid-biopsy cancer detection, treatment selection, recurrence detection and treatment monitoring.
Key Financial Metrics
| Metric | Three Months Ended March 31, 2024 | Three Months Ended March 31, 2023 | Nine Months Ended March 31, 2024 | Nine Months Ended March 31, 2023 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Operating expenses | $17.2 million | $4.1 million | $30.3 million | $15.6 million |
| Loss from operations | $(17.2) million | $(4.1) million | $(30.3) million | $(15.6) million |
| Net loss | $(17.0) million | $(4.3) million | $(30.7) million | $(16.5) million |
| Basic and diluted loss per share | $(0.16) | $(0.08) | $(0.39) | $(0.30) |
| Cash used in operating activities | Not separately provided for the quarter | Not separately provided for the quarter | $(8.6) million | $(9.5) million |
Gross margin and profitability metrics are not meaningful because the company has never generated revenue. The company expects to remain pre-revenue until its therapies or products receive marketing approval and are commercialized.
- Cash and cash equivalents were $312,697 at March 31, 2024, compared with $1.9 million at June 30, 2023.
- Working capital was negative $19.7 million at March 31, 2024, compared with negative $8.5 million at June 30, 2023.
- Total assets increased to $212.3 million from $58.3 million, primarily due to the GEDi Cube acquisition, including $151.5 million of goodwill.
- Total liabilities increased to $43.7 million from $11.8 million, including $20.1 million of contingent consideration, $3.7 million of convertible notes payable and $2.8 million of deferred tax liabilities.
- Debt included $3.4 million of notes payable, net, and $3.7 million of convertible notes payable classified as current liabilities, in addition to lease and other obligations.
- Financing activities provided $8.1 million during the first nine months, including proceeds from notes, private placements and warrant exercises.
Material Changes Versus the Prior Comparable Period
- Quarterly operating expenses increased 323% to $17.2 million, driven by higher general and administrative expense, increased research and development expense and an $8.4 million impairment charge.
- Nine-month operating expenses increased 94% to $30.3 million. General and administrative expense rose 58% to $19.6 million, while research and development expense declined 28% to $2.3 million.
- General and administrative expense increases included legal expenses, non-cash consulting and stock-based compensation, acquisition-related costs, investor relations, marketing and compensation expenses.
- Interest expense increased to $758,057 for the nine-month period from $310,766, reflecting increased debt and discount amortization.
- The company completed the GEDi Cube acquisition for total estimated consideration of $156.6 million, consisting of $136.0 million in common stock and $20.6 million in contingent consideration. GEDi Cube contributed no revenue and a $398,597 net loss from the closing date through March 31, 2024.
- Common shares outstanding increased to approximately 147.5 million at March 31, 2024 from 63.7 million at June 30, 2023, primarily due to the acquisition and other equity issuances.
- The company recorded an $8.4 million impairment after termination of the HV-01 license agreement and abandonment of the related technology.
- Net cash used in operating activities improved modestly from $9.5 million to $8.6 million, but cash declined by $1.6 million during the current nine-month period.
Guidance, Outlook, Risks and Unusual Items
- Management stated that the company’s oncology program, particularly RENB-DC11 for pancreatic and other solid tumors, is the highest priority. IND-enabling activities are targeted for completion in the second half of 2024, with potential human clinical trials in the first half of 2025 if successful.
- Management expects preliminary results from an ongoing non-human-primate study of RENB-HV12 in the second half of 2024 and described potential Pre-IND and Phase 1 timing in 2025.
- Renovaro Cube plans a potential European Union and United Kingdom commercial launch of its AI platform in 2024, but the filing provides no assurance that launch, regulatory clearance, clinical validation, reimbursement or revenue generation will occur.
- The financial statements contain a going-concern qualification. Management reported recurring losses, cash of $312,697, an accumulated deficit of $274.8 million and a working capital deficit of $19.7 million, creating substantial doubt about the company’s ability to continue as a going concern for one year after issuance of the financial statements.
- Management intends to seek additional equity or debt financing and has reduced overhead. Additional financing may be unavailable or may cause significant dilution; failure to obtain funding could require materially reducing or suspending operations or seeking bankruptcy protection.
- The company disclosed a material weakness and ineffective disclosure controls as of March 31, 2024, attributed to inadequate resources for complex accounting matters.
- Material litigation includes a securities class action, federal and state derivative actions, litigation involving former CFO Robert Wolfe, disputes with former licensors and a Delaware action involving alleged registration-rights breaches. The filing does not quantify potential losses or predict outcomes.
- Unusual items include the GEDi Cube acquisition, significant goodwill and contingent consideration, the HV-01 license impairment, non-cash stock-based compensation, warrant exercises applied against debt and substantial equity issuance.
- Subsequent financing included a $150,000 note issued to Paseco ApS on April 9, 2024 and additional notes totaling $855,149 issued to Paseco ApS from April 15 through May 7, 2024.
Most Important Facts for an Investor to Verify
- Verify the filing identity: the supplied document names Renovaro Inc. and covers the period ended March 31, 2024, not Lunai Bioworks Inc. or 2023 Q3.
- Assess near-term liquidity, including the $312,697 cash balance, negative working capital and debt maturities and extensions occurring after March 31, 2024.
- Review the going-concern disclosure and determine whether subsequent financing is sufficient to fund operations, clinical development and commercialization plans.
- Evaluate dilution from the GEDi Cube acquisition, convertible notes, warrants, stock-based compensation and other equity-linked obligations.
- Scrutinize the provisional acquisition accounting, including $151.5 million of goodwill, $44.9 million of IPR&D and $20.1 million of contingent consideration.
- Verify the status, regulatory path and funding requirements for RENB-DC11, RENB-HV12 and Renovaro Cube’s diagnostic platform.
- Review the material weakness in disclosure controls and the company’s remediation plan.
- Monitor pending litigation, license disputes and the potential financial effect of adverse outcomes.